DOI record:
{
"DOI": "10.1186/s12879-021-05773-w",
"ISSN": [
"1471-2334"
],
"URL": "http://dx.doi.org/10.1186/s12879-021-05773-w",
"abstract": "<jats:title>Abstract</jats:title><jats:sec>\n <jats:title>Background</jats:title>\n <jats:p>Hydroxychloroquine has not been associated with improved survival among hospitalized COVID-19 patients in the majority of observational studies and similarly was not identified as an effective prophylaxis following exposure in a prospective randomized trial. We aimed to explore the role of hydroxychloroquine therapy in mildly symptomatic patients diagnosed in the outpatient setting.</jats:p>\n </jats:sec><jats:sec>\n <jats:title>Methods</jats:title>\n <jats:p>We examined the association between outpatient hydroxychloroquine exposure and the subsequent progression of disease among mildly symptomatic non-hospitalized patients with documented SARS-CoV-2 infection. The primary outcome assessed was requirement of hospitalization. Data was obtained from a retrospective review of electronic health records within a New Jersey USA multi-hospital network. We compared outcomes in patients who received hydroxychloroquine with those who did not applying a multivariable logistic model with propensity matching.</jats:p>\n </jats:sec><jats:sec>\n <jats:title>Results</jats:title>\n <jats:p>Among 1274 outpatients with documented SARS-CoV-2 infection 7.6% were prescribed hydroxychloroquine. In a 1067 patient propensity matched cohort, 21.6% with outpatient exposure to hydroxychloroquine were hospitalized, and 31.4% without exposure were hospitalized. In the primary multivariable logistic regression analysis with propensity matching there was an association between exposure to hydroxychloroquine and a decreased rate of hospitalization from COVID-19 (OR 0.53; 95% CI, 0.29, 0.95). Sensitivity analyses revealed similar associations. QTc prolongation events occurred in 2% of patients prescribed hydroxychloroquine with no reported arrhythmia events among those with data available.</jats:p>\n </jats:sec><jats:sec>\n <jats:title>Conclusions</jats:title>\n <jats:p>In this retrospective observational study of SARS-CoV-2 infected non-hospitalized patients hydroxychloroquine exposure was associated with a decreased rate of subsequent hospitalization. Additional exploration of hydroxychloroquine in this mildly symptomatic outpatient population is warranted.</jats:p>\n </jats:sec>",
"alternative-id": [
"5773"
],
"article-number": "72",
"assertion": [
{
"group": {
"label": "Article History",
"name": "ArticleHistory"
},
"label": "Received",
"name": "received",
"order": 1,
"value": "25 August 2020"
},
{
"group": {
"label": "Article History",
"name": "ArticleHistory"
},
"label": "Accepted",
"name": "accepted",
"order": 2,
"value": "6 January 2021"
},
{
"group": {
"label": "Article History",
"name": "ArticleHistory"
},
"label": "First Online",
"name": "first_online",
"order": 3,
"value": "14 January 2021"
},
{
"group": {
"label": "Ethics approval and consent to participate",
"name": "EthicsHeading"
},
"name": "Ethics",
"order": 1,
"value": "Institutional Review Board approval was obtained for access to the prospective observational database (Hackensack Meridian Health under Study# Pro2020–0342). The requirement for patient informed consent, verbal or written, and HIPAA aurthorization was waived by the IRB as this project represented a non-interventional study utilizing routinely collected data for secondary research purposes."
},
{
"group": {
"label": "Consent for publication",
"name": "EthicsHeading"
},
"name": "Ethics",
"order": 2,
"value": "Not applicable."
},
{
"group": {
"label": "Competing interests",
"name": "EthicsHeading"
},
"name": "Ethics",
"order": 3,
"value": "<i>Potential conflicts of interest</i>: AHG reports being a study investigator for Genentech-Hoffman La Roche, during the conduct of the study; research funding as study investigator from Acerta, AstraZeneca, Celgene, Kite Pharma, Elsevier’s PracticeUpdate Oncology, Gilead, Medscape, MJH Associates, OncLive Peer Exchange, Physicians Education Resource, and Xcenda, outside the submitted work, and research funding as a study investigator for Constellation, Infinity, Infinity Verastem, Janssen, Karyopharm, and Pharmacyclics, outside of the submitted work.<i>Potential conflicts of interest:</i> EH report consulting for Regional Cancer Care Associates and Hackensack Meridian Health, outside the submitted work.<i>Potential conflicts of interest:</i> ALP and SLG report having equity ownership in COTA, outside the submitted work.<i>No conflicts of interest:</i> AI, JA, YZ, BAS, UB, MM, ISS, JPU, DMW, RP, RLS, MGP, SLC, FJC, AGC, BLP, DR, GEM, MPE, KLZ, and PM."
}
],
"author": [
{
"ORCID": "http://orcid.org/0000-0003-0456-5618",
"affiliation": [],
"authenticated-orcid": false,
"family": "Ip",
"given": "Andrew",
"sequence": "first"
},
{
"affiliation": [],
"family": "Ahn",
"given": "Jaeil",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Zhou",
"given": "Yizhao",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Goy",
"given": "Andre H.",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Hansen",
"given": "Eric",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Pecora",
"given": "Andrew L.",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Sinclaire",
"given": "Brittany A.",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Bednarz",
"given": "Urszula",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Marafelias",
"given": "Michael",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Sawczuk",
"given": "Ihor S.",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Underwood",
"given": "Joseph P.",
"sequence": "additional",
"suffix": "III"
},
{
"affiliation": [],
"family": "Walker",
"given": "David M.",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Prasad",
"given": "Rajiv",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Sweeney",
"given": "Robert L.",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Ponce",
"given": "Marie G.",
"sequence": "additional"
},
{
"affiliation": [],
"family": "La Capra",
"given": "Samuel",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Cunningham",
"given": "Frank J.",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Calise",
"given": "Arthur G.",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Pulver",
"given": "Bradley L.",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Ruocco",
"given": "Dominic",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Mojares",
"given": "Greggory E.",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Eagan",
"given": "Michael P.",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Ziontz",
"given": "Kristy L.",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Mastrokyriakos",
"given": "Paul",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Goldberg",
"given": "Stuart L.",
"sequence": "additional"
}
],
"container-title": "BMC Infectious Diseases",
"container-title-short": "BMC Infect Dis",
"content-domain": {
"crossmark-restriction": false,
"domain": [
"link.springer.com"
]
},
"created": {
"date-parts": [
[
2021,
1,
14
]
],
"date-time": "2021-01-14T11:03:19Z",
"timestamp": 1610622199000
},
"deposited": {
"date-parts": [
[
2021,
1,
14
]
],
"date-time": "2021-01-14T11:05:00Z",
"timestamp": 1610622300000
},
"indexed": {
"date-parts": [
[
2024,
2,
2
]
],
"date-time": "2024-02-02T06:44:04Z",
"timestamp": 1706856244572
},
"is-referenced-by-count": 36,
"issue": "1",
"issued": {
"date-parts": [
[
2021,
1,
14
]
]
},
"journal-issue": {
"issue": "1",
"published-print": {
"date-parts": [
[
2021,
12
]
]
}
},
"language": "en",
"license": [
{
"URL": "http://creativecommons.org/licenses/by/4.0/",
"content-version": "tdm",
"delay-in-days": 0,
"start": {
"date-parts": [
[
2021,
1,
14
]
],
"date-time": "2021-01-14T00:00:00Z",
"timestamp": 1610582400000
}
},
{
"URL": "http://creativecommons.org/licenses/by/4.0/",
"content-version": "vor",
"delay-in-days": 0,
"start": {
"date-parts": [
[
2021,
1,
14
]
],
"date-time": "2021-01-14T00:00:00Z",
"timestamp": 1610582400000
}
}
],
"link": [
{
"URL": "http://link.springer.com/content/pdf/10.1186/s12879-021-05773-w.pdf",
"content-type": "application/pdf",
"content-version": "vor",
"intended-application": "text-mining"
},
{
"URL": "http://link.springer.com/article/10.1186/s12879-021-05773-w/fulltext.html",
"content-type": "text/html",
"content-version": "vor",
"intended-application": "text-mining"
},
{
"URL": "http://link.springer.com/content/pdf/10.1186/s12879-021-05773-w.pdf",
"content-type": "application/pdf",
"content-version": "vor",
"intended-application": "similarity-checking"
}
],
"member": "297",
"original-title": [],
"prefix": "10.1186",
"published": {
"date-parts": [
[
2021,
1,
14
]
]
},
"published-online": {
"date-parts": [
[
2021,
1,
14
]
]
},
"published-print": {
"date-parts": [
[
2021,
12
]
]
},
"publisher": "Springer Science and Business Media LLC",
"reference": [
{
"author": "A Bhimraj",
"key": "5773_CR1",
"unstructured": "Bhimraj A, Morgan RL, Shumaker AH, Lavergne V, Baden L, Cheng VC, et al. Infectious diseases Society of America guidelines on the treatment and management of patients with COVID-19. 2020. https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/. Accessed 27 Nov 2020.",
"volume-title": "Infectious diseases Society of America guidelines on the treatment and management of patients with COVID-19",
"year": "2020"
},
{
"DOI": "10.1101/2020.10.15.20209817",
"doi-asserted-by": "publisher",
"key": "5773_CR2",
"unstructured": "Pan H, Peto R, Karim QA, Alejandria M, Henao-Restrepo AM, Garcia CH, et al. Repurposed antiviral drugs for COVID-19 -interim WHO SOLIDARITY trial results. medRxiv. 2020. https://doi.org/10.1101/2020.10.15.20209817."
},
{
"key": "5773_CR3",
"unstructured": "New Jersey COVID-19 Information Hub. https://covid19.nj.gov/. Accessed 18 June 2020."
},
{
"key": "5773_CR4",
"unstructured": "Centers for Disease Control and Prevention. https://www.cdc.gov/coronavirus/2019-ncov/covid-data/covidview/index.html. Accessed 27 Nov 2020."
},
{
"DOI": "10.1016/j.ijantimicag.2020.105949",
"doi-asserted-by": "publisher",
"key": "5773_CR5",
"unstructured": "Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020. https://doi.org/10.1016/j.ijantimicag.2020.105949 [published online ahead of print, 2020 Mar 20]."
},
{
"DOI": "10.1371/journal.pone.0237693",
"doi-asserted-by": "publisher",
"key": "5773_CR6",
"unstructured": "Ip A, Berry DA, Hansen E, Goy AH, Pecora AL, Sinclaire BA, et al. Hydroxychloroquine and tocilizumab therapy in COVID-19 patients - an observational study. PLoS One. 2020. https://doi.org/10.1371/journal.pone.0237693."
},
{
"DOI": "10.1056/NEJMoa2012410",
"doi-asserted-by": "publisher",
"key": "5773_CR7",
"unstructured": "Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripcsak G, et al. Observational study of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med. 2020. https://doi.org/10.1056/NEJMoa2012410."
},
{
"DOI": "10.1001/jama.2020.8630",
"doi-asserted-by": "publisher",
"key": "5773_CR8",
"unstructured": "Rosenberg ES, Dufort EM, Udo T, Wilberschied LA, Kumar J, Tesoriero J, et al. Association of Treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York state. JAMA. 2020. https://doi.org/10.1001/jama.2020.8630 [published online ahead of print, 2020 May 11]."
},
{
"DOI": "10.1136/bmj.m1844",
"doi-asserted-by": "publisher",
"key": "5773_CR9",
"unstructured": "Mahévas M, Tran VT, Roumier M, Chabrol A, Paule R, Guillaud C, et al. Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. BMJ. 2020. https://doi.org/10.1136/bmj.m1844 [published correction appears in BMJ. 2020 Jun 18;369:m2328]."
},
{
"DOI": "10.1016/j.ijid.2020.06.099",
"doi-asserted-by": "publisher",
"key": "5773_CR10",
"unstructured": "Arshad S, Kilgore P, Chaudhry ZS, Jacobsen G, Wang DD, Huitsing K, et al. Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19. Int J Infect Dis. 2020. https://doi.org/10.1016/j.ijid.2020.06.099."
},
{
"DOI": "10.1056/NEJMoa2016638",
"doi-asserted-by": "publisher",
"key": "5773_CR11",
"unstructured": "Boulware DR, Pullen MF, Bangdiwala AS, Pastick KA, Lofgren SM, Okafor EC, et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. N Engl J Med. 2020. https://doi.org/10.1056/NEJMoa2016638 [published online ahead of print, 2020 Jun 3]."
},
{
"DOI": "10.1093/cid/ciaa1009",
"doi-asserted-by": "publisher",
"key": "5773_CR12",
"unstructured": "Mitja O, Corbacho-Monné M, Ubals M, Tebe C, Penafiel J, Tobias A, et al. Hydroxychloroquine for early treatment of adults with mild Covid-19: a randomized-controlled trial. Clin Infect Dis. 2020. https://doi.org/10.1093/cid/ciaa1009."
},
{
"DOI": "10.7326/M20-4207",
"doi-asserted-by": "publisher",
"key": "5773_CR13",
"unstructured": "Skipper CP, Pastick KA, Engen NW, Bangdiwala AS, Abassi M, Lofgren SM, et al. Hydroxychloroquine in non-hospitalized adults with early COVID-19: a randomized trial. Ann Intern Med. 2020. https://doi.org/10.7326/M20-4207."
},
{
"key": "5773_CR14",
"unstructured": "Esper RB, da Silva RS, Oikawa FTC, Castro MM, Razuk-Filho A, Batista PB, et al. Empirical treatment with hydroxychloroquine and azithromycin for suspected cases of COVID-19 followed-up by telemedicine. https://pgibertie.files.wordpress.com/2020/04/2020.04.15-journal-manuscript-final.pdf. Accessed 18 June 2020."
},
{
"DOI": "10.9734/ajmah/2020/v18i730224",
"doi-asserted-by": "publisher",
"key": "5773_CR15",
"unstructured": "Guérin V, Lévy P, Thomas JL, Lardenois T, Lacrosse P, Sarrazin E, et al. Azithromycin and hydroxychloroquine accelerate recovery of outpatients with mild/moderate COVID-19. Asian J Med Health. 2020. https://doi.org/10.9734/ajmah/2020/v18i730224."
},
{
"DOI": "10.1016/j.ijantimicag.2020.106214",
"doi-asserted-by": "publisher",
"key": "5773_CR16",
"unstructured": "Scholz M, Derwand R, Zelenko V. COVID-19 outpatients – early risk-stratified treatment with zinc plus low dose hydroxychloroquine and azithromycin: a retrospective case series study. Int J Antimicrob Agents. 2020. https://doi.org/10.1016/j.ijantimicag.2020.106214."
},
{
"DOI": "10.1056/NEJMsb1609216",
"doi-asserted-by": "publisher",
"key": "5773_CR17",
"unstructured": "Sherman RE, Anderson SA, Dal Pan GJ, Gray GW, Gross T, Hunter NL, et al. Real-world evidence - what is it and what can it tell us? N Engl J Med. 2016. https://doi.org/10.1056/NEJMsb1609216."
},
{
"key": "5773_CR18",
"unstructured": "Use of Electronic Health Record Data in Clinical Investigations Guidance for Industry Food and Drug Administration2018 https://www.fda.gov/media/97567/download. Accessed 13 July 2020."
},
{
"key": "5773_CR19",
"unstructured": "Use of real-world evidence to support regulatory decision-making for medical devices: draft guidance for industry and Food and Drug Administration staff. 2017 https://www.fda.gov/media/120060/download. Accessed 13 July 2020."
},
{
"key": "5773_CR20",
"unstructured": "Framework for FDA’s Real-World Evidence Program Food and Drug Administration 2018 updated December 18. Available from: https://www.fda.gov/media/120060/download. Accessed 13 July 2020."
},
{
"DOI": "10.1016/S2665-9913(20)30277-0",
"doi-asserted-by": "publisher",
"key": "5773_CR21",
"unstructured": "Biran N, Ip A, Ahn J, Go RC, Wang S, Mathura S, et al. Tocilizumab among intensive care unit COVID-19 patients: a multi-center observational study. Lancet Rheumatol. 2020. https://doi.org/10.1016/S2665-9913(20)30277-0"
},
{
"DOI": "10.1214/09-STS313",
"doi-asserted-by": "crossref",
"key": "5773_CR22",
"unstructured": "Stuart EA. Matching methods for causal inference: a review and a look forward. Stat Sci 2010;25(1):1–21."
},
{
"DOI": "10.1093/pan/mpl013",
"author": "D Ho",
"doi-asserted-by": "publisher",
"first-page": "199",
"journal-title": "Polit Anal",
"key": "5773_CR23",
"unstructured": "Ho D, Imai K, King G, Stuart E. Matching as nonparametric preprocessing for reducing model dependence in parametric causal inference. Polit Anal. 2007;15:199–236.",
"volume": "15",
"year": "2007"
},
{
"DOI": "10.1016/j.tmaid.2020.101663",
"doi-asserted-by": "publisher",
"key": "5773_CR24",
"unstructured": "Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Sevestre J, Mailhe M, et al. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: a pilot observational study. Travel Med Infect Dis. 2020. https://doi.org/10.1016/j.tmaid.2020.101663."
},
{
"DOI": "10.1016/j.tmaid.2020.101906",
"doi-asserted-by": "publisher",
"key": "5773_CR25",
"unstructured": "Fonseca SN, Sousa AQ, Wolkof AG, Moreira MS, Pinto BC, Takeda CF, et al. Risk of hospitalization for COVID-19 outpatients treated with various drug regimens in Brazil: comparative analysis. Travel Med Infect Dis. 2020. https://doi.org/10.1016/j.tmaid.2020.101906."
},
{
"key": "5773_CR26",
"unstructured": "Hinton DM. Casirivimab and imdevimab EUA Letter of Authorization. https://www.fda.gov/media/143891/download. Accessed 27 Nov 2020."
},
{
"DOI": "10.1007/s11606-020-06146-w",
"doi-asserted-by": "publisher",
"key": "5773_CR27",
"unstructured": "Elavarasi A, Prasad M, Seth T, Sahoo RK, Madan K, Nischal N, et al. Chloroquine and Hydroxychloroquine for the treatment of COVID-19: a systematic review and meta-analysis. J Gen Intern Med. 2020. https://doi.org/10.1007/s11606-020-06146-w."
},
{
"DOI": "10.1016/j.ijantimicag.2020.105954",
"doi-asserted-by": "publisher",
"key": "5773_CR28",
"unstructured": "Zhang C, Wu Z, Li JW, Zhao H, Wang GQ. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. Int J Antimicrob Agents. 2020. https://doi.org/10.1016/j.ijantimicag.2020.105954."
},
{
"DOI": "10.1007/s00281-017-0629-x",
"author": "R Channappanavar",
"doi-asserted-by": "publisher",
"first-page": "529",
"issue": "5",
"journal-title": "Semin Immunopathol",
"key": "5773_CR29",
"unstructured": "Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. 2017;39(5):529–39.",
"volume": "39",
"year": "2017"
},
{
"DOI": "10.1016/S0140-6736(20)30183-5",
"author": "C Huang",
"doi-asserted-by": "publisher",
"first-page": "497",
"journal-title": "Lancet",
"key": "5773_CR30",
"unstructured": "Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506.",
"volume": "395",
"year": "2020"
},
{
"DOI": "10.1007/s00281-017-0640-2",
"author": "JR Teijaro",
"doi-asserted-by": "publisher",
"first-page": "501",
"issue": "5",
"journal-title": "Semin Immunopathol",
"key": "5773_CR31",
"unstructured": "Teijaro JR. Cytokine storms in infectious diseases. Semin Immunopathol. 2017;39(5):501–3.",
"volume": "39",
"year": "2017"
},
{
"DOI": "10.1056/NEJMoa2021436",
"doi-asserted-by": "publisher",
"key": "5773_CR32",
"unstructured": "Horby P, Lim WS, Emberson J, Mafham M, Bell JL, Linsell L, et al. Effect of dexamethasone in hospitalized patients with COVID-19: preliminary report. N Engl J Med. 2020. https://doi.org/10.1056/NEJMoa2021436."
},
{
"DOI": "10.1016/j.autrev.2020.102568",
"doi-asserted-by": "publisher",
"key": "5773_CR33",
"unstructured": "Toniati P, Piva S, Cattalini M, Garrafa E, Regola F, Castelli F, et al. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: a single center study of 100 patients in Brescia, Italy. Autoimmun Rev. 2020. https://doi.org/10.1016/j.autrev.2020.102568."
},
{
"DOI": "10.1016/j.tmaid.2020.101738",
"doi-asserted-by": "publisher",
"key": "5773_CR34",
"unstructured": "Million M, Lagierab JC, Gautret P, Colson P, Fournier PE, Amrane S, et al. Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: a retrospective analysis of 1061 cases in Marseille, France. Travel Med Infect Diss. 2020. https://doi.org/10.1016/j.tmaid.2020.101738."
},
{
"DOI": "10.1093/aje/kwaa093",
"doi-asserted-by": "publisher",
"key": "5773_CR35",
"unstructured": "Risch HA. Early outpatient treatment of symptomatic, high-risk Covid-19 patients that should be ramped-up immediately as key to the pandemic crisis. Am J Epidemiol. 2020. https://doi.org/10.1093/aje/kwaa093."
},
{
"DOI": "10.1101/2020.09.30.20204693",
"doi-asserted-by": "publisher",
"key": "5773_CR36",
"unstructured": "Ladapo JA, McKinnon JE, McCullough PA, Risch H. Randomized controlled trials of early ambulatory hydroxychloroquine in the prevention of COVID-19 infection, hospitalization, and death: meta-analysis. MedRxiv. 2020. https://doi.org/10.1101/2020.09.30.20204693."
},
{
"DOI": "10.1097/RCT.0000000000001075",
"author": "AAKA Razek",
"doi-asserted-by": "publisher",
"first-page": "656",
"journal-title": "J Comput Assist Tomogr",
"key": "5773_CR37",
"unstructured": "Razek AAKA, El Badrawy MK, Alnaghy E. Interstitial lung fibrosis imaging reporting and data system: what radiologist wants to know? J Comput Assist Tomogr. 2020;44:656–66.",
"volume": "44",
"year": "2020"
},
{
"DOI": "10.7303/syn22909530",
"doi-asserted-by": "publisher",
"key": "5773_CR38",
"unstructured": "Ip A, Ahn J, Goldberg SL. Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: a multi-center observational study dataset. 2020. https://doi.org/10.7303/syn22909530 Synapse: https://www.synapse.org/#!Synapse:syn22909530/files/."
}
],
"reference-count": 38,
"references-count": 38,
"relation": {},
"resource": {
"primary": {
"URL": "https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-021-05773-w"
}
},
"score": 1,
"short-title": [],
"source": "Crossref",
"subject": [
"Infectious Diseases"
],
"subtitle": [],
"title": "Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: a multi-center observational study",
"type": "journal-article",
"update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy",
"volume": "21"
}
